ACTG 316--NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL/FETAL HIV

ACTG 316--奈韦拉平与奈韦拉平安慰剂预防孕产妇/胎儿艾滋病毒的比较

• 批准号: 6116906
• 负责人: Stuart E Starr
• 金额: $ 2.47万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116906
• 关键词: AIDS education /prevention; AIDS therapy; AIDS vaccines; HIV infections; chemoprevention; clinical research; clinical trials; data collection methodology /evaluation; drug screening /evaluation; human subject; human therapy evaluation; nevirapine; vertical transmission

To date, 5 mother infant pairs have been enrolled in this study at CHOP and its associated perinatal subunits. To date, 3 infants have been born and are undergoing follow-up and data collection. Nationwide, the study has accrued >150 mother-infant pairs to date with a target accrual goal of 1244 mother-infant pairs. No preliminary data are yet available from this study.

迄今为止，CHOP的本研究已入组5对母婴 及其相关的围产期亚基。到目前为止，已有3名婴儿出生， 并正在进行跟进和数据收集。在全国范围内，这项研究 迄今为止，已累计超过150对母婴，目标累计目标为 1244对母婴。目前还没有初步的数据 study.